The Stem Cell Podcast is hosted by Christopher Fasano PhD and Yosif Ganat PhD and is dedicated to the field of stem cells. Possible cures, therapies and breakthroughs will be discussed including featured interviews with pioneering stem cell scientists.
A video podcast by the American Society for Microbiology that highlights the latest in microbiology, life science and biotechnology news. ASM is composed of over 42,000 scientists and health professionals with the mission to advance the microbial sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide. For information about ASM and MicrobeWorld, visit us online at www.microbeworld.org. For questions and/or feedback please email firstname.lastname@example.org.
Anna Kavanaugh hosts the weekly radio series, "Mad Science: The Genetic Crossroad." The program aims to raise awareness and provide education about genetically modified organisms (GMO), in the world food supply and the practices of the GM biotech industry. The series is dedicated to all issues surrounding GM foods, its usage and ramifications thereof. Anna is a writer, advocate, and founder of the (AKCF) Anna Kavanaugh Charitable Foundation. Her original novel, "The Cord of Callows," now an upcoming expanded trilogy series, is the inspiration for a GMO documentary film entitled, "The Cord of Callows trilogy: Fact Behind the Fiction. Fear Behind the Fact."
A large number of clinical trials underlying the approval of drugs never come into public view. This not only has legal and ethical ramifications, but implications for the healthcare system as a whole. We spoke to Jennifer Miller, founding president of Bioethics International and assistant professor at the NYU School of Medicine about her recent study in BMJ Open, part of an effort to improve transparency through the creation of a Good Pharma Scorecard. Miller discussed the study, the scorecard, and the state of transparency in the pharmaceutical industry.
Thanks for tuning in for Episode 58, “Heart Disease Modeling” featuring Dr. Lior Gepstein. This and all of our episodes are sponsored by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for the newsletter. We begin as always with the Science Round Up and discuss the latest science/stem cell news including: Discovery of a new STD. Stem cells generated from urine used to help discover new drugs for cholesterol disease? A new stem cell method to model diseases of the muscle. A stem cell company bought out for 380 million dollars. Impaired sense of smell may indicate dementia. More NFL stars going for stem cell therapies. For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on clinician and researcher Dr. Lior Gepstein to discuss his work on using stem cells to model heart disease. We talk to Dr. Gepstein about his past and current work including his latest paper published in Stem Cell Reports. Finally we close th ...
Vincent take This Week in Microbiology to the University of California, San Diego campus and into the the laboratories of Kit and Joseph Pogliano, where he learns about their work on the bacterial cytoskeleton, sporulation, and the effects of antibiotics on bacterial cells.
By email@example.com (American Society for Microbiology)
The power of genetic engineering will soon be available for the home thanks to the Amino One, a piece of hardware about the size of a laptop computer that would allow users to manipulate the DNA of microorganisms for productive purposes or just plain fun. We spoke to Julie Legault, founder and CEO of Amino One’s creator Amino Labs, about the device, its target market, and the implications of putting the tools of synthetic biology into the hands of kids.
New gene editing technologies are expanding the ease and power with which scientists can manipulate biological systems with the promising of addressing not only human health issues, but problems the plant faces with regards to food, fuel, and the environment. But while much of the concerns raised about the potential consequences of this technology have focused on its use in humans, Elizabeth Alter, assistant professor of biology at City University of New York’s York College, argues its potential environmental implications will likely be far more significant. We spoke to Alter about her recent op-ed in The New York Times, the need for public discussion about the technology, what should be done today as we work through broader questions of policy.
Mad Science: The Genetic Crossroad With Anna Kavanaugh
One of the latest practices in biotech is a process that allows DNA to be edited down to the letter. Known as CRISPR technology, scientists now have the ability to control gene mechanisms with unprecedented accuracy and without traditional invasive high-cost GMO procedures as they exist now. In effect, CRISPR is the evolution of GMO. All of this allows corporations to continue producing genetically altered foods without ever having to worry about legislation or labeling mandates. As consumer "right to know" demand increases and more companies are responding to protests by voluntarily labeling GMO products or removing them from their ingredients altogether, industry is well ahead of the game and consumers should not be fooled into complacency. CRISPR technology allows a crafty bypass because it is not recognized technically as a GMO process as is currently defined. Industry can use this technology to dodge existing regulations now, or in the future, and avoid GMO stigmas in public p ...
Thanks for tuning in for Episode 57, “Curiosity” featuring Duane Fernandez. This and all of our episodes are sponsored by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for the newsletter. We begin as always with the Science Round Up and discuss the latest science/stem cell news including: A woman that can smell Parkinson’s disease? Will we ever be able to treat female infertility with stem cells? A new gene that regulates the stem cell number A new stem cell model of bi-polar disorder A common allergy medication might help your brain For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on writer, director and photographer Duane Fernandez to talk about how curiosity drives him and his work. We talk to Duane on his experience with helping people from all walks of life and business experience their true potential and how this can apply to science. Finally we close the show with our signature rant on labeling t ...
Vincent, Elio, and Michele meet with Harry Mobley, Mary O’Riordan, and Vince Young at the University of Michigan, during the designation of the Department of Microbiology and Immunology as a Milestones in Microbiology site. They discuss how the laboratory has advanced the science and teaching of microbiology, and discuss faculty work on uropathogenic E. coli, induction of stress by bacterial infection, and the gut microbiome.
By firstname.lastname@example.org (American Society for Microbiology)
The U.S. Securities and Exchange Commission last week finalized rules on crowdfunding that opens the door for the participation of non-accredited investors. The rules complete a long process for the commission set into motion by the passage of the JOBS Act. We spoke to Richard Swart, director of research for the Program for Innovation in Entrepreneurial and Social Finance at the University of California at Berkeley and chief strategy officer for the crowdfunding investment site NextGen Crowdfunding, about the new rules, how this will change the investment landscape, and what it all means for the biotech industry.
Mad Science: The Genetic Crossroad With Anna Kavanaugh
Throughout the GMO, biotech and agrochemical debates, we have witnessed the ultimate in corporate control and influence along with the disastrous impacts from the implementation of these technologies in our world food supply, pharmaceuticals, and the reckless tampering of DNA for profit-driven purposes. These impacts pose drastic effects to our human health and evolutionary process in a variety of ways. However, there is another critical aspect to the larger picture of which we are not talking enough about: the frightening consequences resulting from the biotech industry that now compromise the delicate balance of our planetary ecology and environment. As the hand of biotech continues to sweep across and outright ignore all reasonable boundaries of ethics and morality in its unquenchable thirst for power and profit, how close are we to the final curtain-call where nature, in its own inevitable wisdom, will protest against us and what cost will future generations have to pay for the ...
Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI on October 30. Both Peter and Pepper will be speaking at CHI’s Third Annual Advances in Prenatal Molecular Diagnostics conference, taking place in Boston on November 16-18. Topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.HealthTech.com/Prenatal-Diagnostics/
Growing challenges in the areas of health, food, energy, and the environment have increased efforts to harness biology to create sustainable solutions to global problems. With advances in the ability to engineer microbes to perform desired tasks, the rapidly evolving area of synthetic biology is expected to fundamentally reshape industrial processes and give rise to a new bioeconomy. Leading scientists, entrepreneurs, and investors will gather in San Francisco November 4 through 6 for SynBioBeta SF 2015 to explore the state of synthetic biology. We spoke to Richard Kitney, professor of biomedical systems engineering at Imperial College London and one of the leading scientists behind the United Kingdom’s efforts in synthetic biology, about the upcoming conference, where the state of the science is today, and why scaling up to industrial sized processes remains a big challenge.
Thanks for tuning in to Episode 56, Glia featuring Dr. Steven Goldman. This and all of our episodes are sponsored by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for our newsletter. We begin as always with the #SciRoundUp and discuss the latest science and stem cell news including: Diamonds can detect cancer? A vaccine for AIDS brought to the clinic An “in womb” stem cell trial to begin? Stem cell burgers coming soon Stem cells to alleviate dementia For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on stem cell expert Dr. Steven Goldman from the University of Rochester to talk about glial cells and his work using stem cells to model and fix diseases like Multiple Sclerosis using Neural Stem Cells. Finally, we close the show with our signature rant on: “when someone tells you, you look tired.” Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the resea ...
Watch the pilot episode of BioFilms in which we explore some creepy microbes just in time for Halloween. Learn how algae can suffocate a pond of all its life, discover the vampire bacterium known as Vampirococcus who literally sucks the life out its victims, and watch out for those sweet Halloween treats that can leave holes in your teeth!
By email@example.com (American Society for Microbiology)
Vincent meets up with Romney and Duncan at the 79th annual meeting of the Southern California branch of the American Society for Microbiology, where they talk about emerging technologies for antimicrobial susceptibility testing, and next generation sequencing and advanced molecular diagnostics. Visit microbeworld.org/twim for complete shownotes including links mentioned.
By firstname.lastname@example.org (American Society for Microbiology)
A new class of immunotherapies is promising to radically alter the treatment of cancers and has generated excitement among investors for their groundbreaking potential. Now the Loncar Cancer Immunotherapy ETF provides a way for investors to bet on the sector through an exchange traded fund that consists of both Big Pharma and emerging growth biotechs leading the sector. We spoke to Brad Loncar, CEO of Loncar Investments and creator of the ETF, about the fund, why the focus on this narrow slice of the biotech world, and why he thinks immunotherapies will dramatically reshape cancer care in the years ahead.
Wall Street doesn’t like uncertainty and there are a number of policy issues now brewing that threaten to create some uncertainty for the biotechnology industry. As the BIO Investor Forum kicks off in San Francisco October 20 and 21, bringing together investors and CEOs for two days of panels and presentations, the conference will turn its attention to policy issues and the effects they have on valuations within this industry. We spoke to Sara Radcliffe, president and CEO of the California Life Sciences Association and a policy panelist and the BIO Investor Forum, about policy issues the industry faces, the growing controversy over pricing, and what policy matters investors should be watching.
Happy Stem Cell Awareness Day SCP fans and welcome to Episode 55. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin this episode by answering some questions from you the audience, thank you to everyone that submitted their questions and apologies to those that we could not get to. After this we do a mini-Science Roundup sponsored by Thermo Fisher including: Creation of rudimentary kidneys from stem cells A new method to generate “old” neurons A new company created to create genetically modified pigs Flowing water found on Mars For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on Dr. David Mooney, Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences to discuss his work using Biomaterials to help stem cells more efficiently integrate after transplantation. We then finish off the show with a rant on automatic flushing toilets. Enjoy! Below are all of the pape ...
The medtech industry has enjoyed robust M&A activity, strong financings, and a rise in R&D investments, but other numbers point to troubling developments that threaten the future health and growth of the industry, according to a new report from EY. We spoke to Ellen Licking, EY Life Sciences lead analyst, about the report, concerns about the venture capital industry’s move away from the sector, and questions about who will fund early-stage innovation that will be necessary for the future growth of the industry.
Vtesse, a rare disease drug development company, this week announced that it was initiating a late-stage pivotal trial for its lead experimental therapeutic to treat Niemann-Pick Type C1 disease. The start of the trial for the nine month old company represents a major milestone and suggest its history with the National Institutes of Health and the rare disease drug accelerator Cydan Development may point to new ways of cutting the time and cost of advancing a drug to market. We spoke to Ben Machielse, CEO of Vtesse, about the rapid pace at which the company has been able to move, the role NIH has played, and whether this points to new ways to accelerate the drug development process.
Welcome everyone to Episode 54. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode, we discuss topics ranging from: A new type of cells called calendar cells STAP cells finally put to bed An amazing visualization of the bone marrow stem cell niche A new CRISPR enzyme discovered Standing up and getting dizzy might mean bad things for you down the line GMP stem cell manufacturing Predictions for the Nobel prize awards announced next week A new drug for Alzheimer’s And much more… For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on Dr. Andrew Cohen, Associate Professor at Drexel University, to discuss his work on creating new software and programs to track stem cell lineages using time lapse video data. We then finish off the show with a rant on “double dipping.” Enjoy! Below are all of the papers mentioned on the ...
CHI chats with Rebekah S. Zimmerman, Ph.D., FACMG, Director, Clinical Genetics, Foundation for Embryonic Competence. Dr. Zimmerman discuss the latest technologies she and her non-profit lab are working with and developing, including how the non-profit lab is different from a typical PGD lab. Dr. Zimmerman is one of our speakers for the Advances in NGS and Other Technologies session at the Reproductive Genetic Diagnostics conference. For details, visit http://www.Healthtech.com/Reproductive-Genetic-Diagnostics
The U.S. Department of Health and Human Services has been working to move Medicare from fee-for-service to value-based payments. It’s seeking to get 90 percent of payments to being value-based by 2018. The problem, according to a recent Viewpoint in JAMA, is that when addressing life-ending chronic conditions faced by older patients, traditional professional standards that drive today’s metrics don’t effectively address patient desires. We spoke to Joanne Lynn, director of the Altarum Institute’s Center for Elder Care and Advanced Illness and lead author of the JAMA Viewpoint, about what value-based care means for patients near the end of their lives, the need to recognize the great variance in patient desires, and how healthcare systems will need to change to account for this.
The California legislature earlier this month passed a bill that would allow physicians to aid terminally ill patients who wanted to end their lives. California would become the fifth state to enact such legislation. We spoke to David Grube, national medical director of Compassion & Choices, a nonprofit working to expand end of life options, about the legislation, how attitudes among the public and physicians have changed, and what we’ve learned since Oregon passed the first such law 17 years ago.
Welcome SCP fans to Episode 53. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode, we discuss topics ranging from a new human species discovered, a study showing how many trees exist, the new winner of the new Ogawa and Yamanaka award, the new “unicorn” company Stemcentrx and what they’re up to, a new way to track the way stem cells divide, liver stem cells, robots making IPS cells, resin from a tree can be a new epilepsy treatment, sleep deprivation is the main risk factor for a cold, and melatonin contributes to the seasonality of multiple sclerosis. For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on Dr. Scott Noggle, VP of Stem Cell Research at The New York Stem Cell Foundation to discuss their automated system for making IPS cells. We then finish off the show with a rant on mistaking zeroes (0) for the le ...
The U.S. Food and Drug Administration recently released long-awaited draft guidance regarding the naming of biologics, biosimilars, and interchangeable biologics. At the same time the agency released a proposed rule to apply the naming scheme to six current biological products with, or expected to soon have, biosimilar competitors. We spoke to Gillian Woollett, senior vice president with the healthcare business strategy and public policy advisory firm Avalere Health, about the FDA’s actions, their implications, and some potential unintended consequences.
The National Comprehensive Cancer Network in October will release a new tool designed to help doctors understand the value of different cancer therapies by taking into account the costs of treatments. The effort from the influential group follows similar initiatives by Sloan Kettering Cancer Center and the American Society of Clinical Oncology. We spoke to Bob Carlson, CEO of the National Comprehensive Cancer Network, about the rising costs of cancer care, the new tool, and what impact it will likely have on drug pricing in the future.
Welcome SCP fans to Episode 52 and thanks as always for tuning in. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode, we discuss topics ranging from STAP author accusations, stem cells go to space, different types of bacteria in homes, tricking the body to fight colon cancer stem cells, growing a human brain in the lab, the female “viagra” is now available, and much more. For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on Dr. Flora Vaccarino from Yale University to discuss stem cells and autism, specifically her work on neural stem cells and how she is using them to study Autism Spectrum Disorder. We then finish off the show with a rant on the metal tops to Matrigel. Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possib ...
Dr. Niall Barron of Dublin City University speaks to CHI on August 28, 2015. Dr. Barron will be presenting during the Engineering Expression Systems conference at the 2015 PEGS Europe Summit, 2-6 November in Lisbon, Portugal. Topics include CHO cell line engineering, accelerating recombinant protein production with existing and novel expression platforms, challenges, microRNA manipulation to boost recombinant protein productivity and manufacturing of biopharmaceuticals in Ireland. For more information, please visit http://www.PEGSummitEurope.com/
Host: Vincent Racaniello Guest: Michele Banks Vincent meets up with Michele Banks in Washington, DC to discuss her career as a creator of science-themed art. Links for this episode: Michele Banks on Twitter https://twitter.com/artologica Artologica https://www.etsy.com/people/artologica Michele's blog http://artologica.blogspot.com The Finch and the Pea http://thefinchandpea.com Joseph Cornell https://en.wikipedia.org/wiki/Joseph_Cornell Not Exactly Rocket Science (Ed Yong) http://phenomena.nationalgeographic.com/blog/not-exactly-rocket-science/ Tree of Life (Jonathan Eisen) http://phylogenomics.blogspot.com Home Microbiome Study http://homemicrobiome.com Kitten Microbiome Project http://www.kittenmicrobiome.org Science Online http://scienceonline.com The Vexed Muddler https://www.etsy.com/shop/theVexedMuddler Luke Jerram http://www.lukejerram.com A Daily Dish (Klari Reis) http://www.adailydish.com Neuroscience art (Greg Dunn) http://www.gregadunn.com Ai Weiwei https://en.wikipedia ...
By email@example.com (American Society for Microbiology)
President Jimmy Carter, at a recent press conference discussing his cancer diagnosis and treatment, expressed his wish to outlive the last Guinea worm. The Carter Center, since 1986, has led a global effort to eradicate Guinea worm disease with great success and its goal is within reach. We spoke to Ernesto Ruiz-Tiben, director of The Carter Center’s Guinea Worm Eradication Program, about its efforts, the history behind it, and what lessons can be drawn in combating other public health threats throughout the world.
Sprout Pharmaceuticals earlier this week won a controversial U.S. Food and Drug Administration approval of Addyi, the first drug approved in the United States to treat female sexual dysfunction. Following the news, Valeant Pharmaceuticals said it would acquire Sprout for $1 billion. We spoke filmmaker Liz Canner, director of the documentary Orgasm, Inc., about Addyi, the drug industry’s long standing pursuit of a female Viagra, and why its approval is troubling to many people.
Welcome SCP fans to Episode 51. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode, we discuss topics ranging from gene drive, liver stem cells, robots making iPS cells, a bacteria that eats nicotine, genetic analysis of people with high intelligence, and much more. We next move to the interview segment of the show, sponsored by STEMCELL Technologies. Our guest today is Thermo Fisher collaborator Dr. Chris Armstrong, CEO of Stem Cell Theranostics to discuss his company and how they are using iPSCs to model cardiovascular disease. We then finish off the show with a rant on elastic socks. Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your name and e-mail address below, and we will notify you of when this featu ...
Earlier this month in a preemptive challenge from Amarin Pharma against the U.S. Food and Drug Administration a federal judge ruled that the FDA cannot prohibit a drugmaker from promoting the off-label use of a drug if it does so through the dissemination of truthful and non-misleading information. The decision about the First Amendment Rights of a pharmaceutical company is seen as a significant ruling in a long-standing battle between the agency and the industry that has played out over the past 20 years. We spoke to John Kamp, executive director of the Coalition for Healthcare Communication, about the case, the issues behind it, and its implications for how the industry and agency will act going forward.
CHI chats with Tanmoy Mukherjee, M.D., Assistant Clinical Professor, Obstetrics, Gynecology and Reproductive Science, Mount Sinai Hospital. Dr. Mukherjee discusses the current challenges facing reproductive specialists in regards to genetic diagnosis of recurrent pregnancy loss, as well as how NGS is affecting this type of testing Dr. Mukherjee is one of our speakers for the Clinical Applications for Advanced Testing Technologies session at the Reproductive Genetic Diagnostics conference. For details, visit http://www.healthtech.com/reproductive-genetic-diagnostics
CHI interviews Dr. Claudio Hetz, Professor in the Institute of Biomedical Sciences, and Principal Investigator in the Laboratory of Cellular Stress and Biomedicine at the University of Chile about the rapidly evolving drug discovery space of targeting the unfolded protein response (UPR) - particularly for cancers and neurodegenerative diseases. Discussion questions include: • Why has targeting components of the UPR emerged as a viable therapeutic strategy? (What are some of the recent critical discoveries that have propelled this field forward?) • What are emerging and promising therapeutic targets within the UPR and why? • What are some of the current challenges surrounding targeting the UPR? • You are giving a lecture during the upcoming Targeting the Unfolded Protein Response meeting, September 23-24 in Boston. Can you tell us a little about your work and what you hope to convey to attendees during the conference? • What are people within this space just now starting to think ab ...
Drugmakers about 10 percent of the time fail to report serious adverse events to the U.S. Food and Drug Administration within the time required, according to a recent study in the Journal of the American Medical Association. We spoke to Pinar Karaca-Mandic, study co-author and associate professor of Health Policy and Management at the School of Public Health at the University of Minnesota, about the study, the concerns it raises, and whether regulators need to rethink the way adverse events are reported.
Bonus Podcast for CHI's interview with Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio Listen to the full podcast here: https://soundcloud.com/chi-podcasts/histone-methyltransferase-and-demethylase-inhibitor-discovery Find more information about the conference here: http://www.DiscoveryOnTarget.com/
The Stem Cell Podcast is proud to bring you our 50th Episode. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode, we discuss topics ranging from the US going to Pluto, a fast growing black hole, discovery of taste of fat, planned parenthood selling fetal tissue, stem cell stocks, functional liver cells from stem cells and more. For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on internationally recognized stem cell pioneer Dr. George Daley from Children’s Hospital Boston and the Harvard Stem Cell Institute to discuss all things stem cells. We then finish off the show with a rant on wobbly tables. Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the research papers we mention and possibly even provide audio summaries. Enter in your name and e-mail address bel ...
A growing problem with drug resistant infections acquired in hospitals is catching the eye of Consumer Reports, which has added the incidence of two common and deadly infections to their hospital ratings. The ratings come in the second part of a three-part investigation in the antibiotic crisis. We spoke to Doris Peter, director of Consumer Reports’ Health Ratings Center, about the study, what the highest rated hospitals are doing that the lower rated ones are not, and things patients can do to safeguard themselves when they face a hospital stay.
CHI interviews Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio about the current challenges in developing novel chemical matter targeting HMTs and HDMs, novel tools and technologies enabling discovery, and emerging targets within this space. Discussion questions include: 1. How have you seen this field evolve over the past few years? 2. What are some of the challenges in developing novel chemical matter targeting these enzymes? 3. What are some of the tools and technologies that are aiding epigenetic inhibitor discovery? 4. What are some other interesting and emerging HMT or HDM targets? 5. You are giving a lecture during the upcoming Targeting Histone Methyltransferases and Demethylases meeting, part of Discovery on Target 2015 this September 23-24 in Boston. What do you hope to share with attendees during your lecture? Find more information at http://www.DiscoveryOnTarget.com/
The controversy over the high price of new drugs and the question of the value they provide will come under increased scrutiny thanks to a grant to a Boston-based nonprofit that works to get at these questions. The Laura and John Arnold Foundation this week announced it is providing $5.2 million to the Institute for Clinical and Economic Review aimed at transforming the way new drugs are evaluated and priced. We spoke to Sarah Emond, COO of the institute, about the work it does, what this new grant will do to expand that work, and how to get a the question of the value of new drugs.
Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens.
By firstname.lastname@example.org (Nature Biotechnology)
Welcome everybody to Episode 49, be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. In this episode we give you the second part of our broadcast live from the ISSCR 2015 International Conference from Stockholm, Sweden. On the show, we randomly pull attendees aside and ask them to us their stem cell story, and detail some of their research topics and accomplishments. Some of those interviewed on the show include Dr. Sean Morrison, the President of ISSCR, and Dr. Paul Tesar of Case Western Reserve University. Because we have over 2 hours of audio, we will not do a Thermo Fisher sponsored, science roundup. After the interviews we close the show with a signature SCP rant. The post Ep. 49: SCP Sweden Part 2 – Live Interviews from the ISSCR Conference in Sweden 2015 appeared first on Stem Cell Podcast.
Researchers at the University of California, Berkeley and the Gladstone Institutes have grown beating cardiac tissue from stem cells in work that may lead to new ways to quickly screen for drugs likely to cause birth defects in the heart and identify drugs that may be dangerous during pregnancy. We spoke to Bruce Conklin, a senior investigator at the Gladstone Institute of Cardiovascular Disease, about the work, which was published in the journal Nature Communications, the promise it has for providing more accurate insights than animal models, and whether the approach could be expanded to other cell types to screen for drug toxicity to other organs.
For many patients with rare and difficult to diagnose conditions, it can take many years and many doctors to find a correct answer. CrowdMed is trying to offering an alternative to patients by allowing them to tap the wisdom of crowds and letting medical detectives who sign on to the site try to find the right answer. We spoke to Jared Heyman, founder and CEO of CrowdMed, about the problem with the traditional way doctors diagnose patients, the wisdom of crowds, and the case for making medicine a team sport.
Giulia Siravegna of the University of Torino and the IRCCS-Candiolo Cancer Institute discusses the recent study on the potential of circulating tumor DNA (ctDNA) to evaluate response to chemotherapy in colorectal cancer patients; how ctDNA will be used in conjunction with other tests in the standard of care for colorectal cancer; exciting applications emerging for liquid biopsies; and results from the recent liquid biopsy study published in Nature. Find more at http://www.NextGenerationDx.com/Cell-Free-DNA Watch the interview at https://youtu.be/JHD9YR4NYX0
Welcome everybody to Episode 48, be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. In this episode we broadcast live from the ISSCR 2015 International Conference from Stockholm, Sweden. On the show, we randomly pull attendees aside and ask them to us their stem cell story, and detail some of their research topics and accomplishments. Everyone from graduate students, post-docs, patients who have received stem cell transplants, to big name researchers, we get them all. This episode will be part one, with part two continuing into Episode 49. Because we have over 2 hours of audio, we will not do a Thermo Fisher sponsored, science roundup. After the interviews we close the show with a signature SCP rant. The post Ep. 48: SCP Sweden Part 1 – Live Interviews from the ISSCR Conference in Sweden 2015 appeared first on Stem Cell Podcast.